Regeneron Pharmaceuticals
REGN
702 hedge funds and large institutions have $27.7B invested in Regeneron Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 136 funds opening new positions, 205 increasing their positions, 250 reducing their positions, and 54 closing their positions.
220% more funds holding in top 10
Funds holding in top 10: 5 → 16 (+11)
152% more first-time investments, than exits
New positions opened: 136 | Existing positions closed: 54
36% more capital invested
Capital invested by funds: $20.4B → $27.7B (+$7.35B)
11% more funds holding
Funds holding: 632 → 702 (+70)
0.17% more ownership
Funds ownership: 68.3% → 68.47% (+0.17%)
16% less call options, than puts
Call options by funds: $773M | Put options by funds: $924M
18% less repeat investments, than reductions
Existing positions increased: 205 | Existing positions reduced: 250
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$257M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$181M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$166M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$162M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$160M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$337M |
| 2 |
Parnassus Investments
San Francisco,
California
|
-$161M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$122M |
| 4 |
Millennium Management
New York
|
-$82.9M |
| 5 |
Two Sigma Advisers
New York
|
-$82.2M |
REGN Hedge Fund Activity: Q4 2019 in Review
702 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q4 2019, worth a combined $27.7B — up 36% from $20.4B a quarter earlier.
Buyers outnumbered sellers: 136 funds opened new REGN positions and 54 closed out — a net gain of 82 holders — while 205 added to existing stakes and 250 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $257M. The largest seller was Invesco, cutting an estimated $337M.
- 702 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q4 2019, up from 632 in Q3 2019.
- Funds reported $27.7B of Regeneron Pharmaceuticals stock for Q4 2019, up 36% quarter-over-quarter.
- 136 funds opened new Regeneron Pharmaceuticals positions in Q4 2019 and 54 closed out, a net change of +82 holders.
- The largest Regeneron Pharmaceuticals buyer in Q4 2019 was JP Morgan Chase, an estimated $257M added.
- The largest Regeneron Pharmaceuticals seller in Q4 2019 was Invesco, an estimated $337M sold.
Based on aggregated 13F filings for Q4 2019.